Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium.

BACKGROUND: Turkey is an intermediate hepatitis B virus (HBV) endemic country. However, prevalence among Turkish migrants in Belgium is unknown, especially in those born in Belgium with a foreign-born parent, i.e. second-generation migrants (SGM). AIMS: To evaluate the prevalence of HBV infection and associated risk factors in Turkish first-generation migrants (FGM), i.e. foreign-born, and SGM.
METHODS: Between September 2017 and May 2019, free outreach testing for hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc), and antibodies against HBsAg was offered to Turkish migrants in Middle-Limburg, Belgium. Face-to-face questionnaire assessed HBV risk factors. HBsAg positive patients were referred and followed up. Turkish SGM were stratified into birth cohort born before and after 1987, since those born after 1987 should be covered by the universal infant vaccination program.
RESULTS: A total of 1,081/1,113 (97.1%) Turkish did go for HBV testing. Twenty-six (2.4%) were HBsAg positive; 11/26 were unaware of their status and 10/11 were successfully referred. HBsAg prevalence was 3.0% in FGM and 1.5% in SGM, p = .070. Only one out of seven HBsAg positive SGM was born after 1987. In the multiple generalized estimating equations model, the most important risk factors for anti-HBc positivity were male gender (p = .021), older age (p < .001), FGM (p < .001), low educational level of the mother (p = .003), HBV infected mother (p = .008), HBV infected siblings (p = .002), HBV infected other family member (p = .004), gynaecological examination in Turkey or unsafe male circumcision (p = .032) and dental treatment in Turkey (p = .049).
CONCLUSION: Outreach testing was well-accepted and referral to specialist care was generally successful. National HBV screening should be implemented in the Turkish FGM population and might be considered in SGM not covered by primary prevention strategies.

Introduction

Hepatitis B virus (HBV) infection is one of the most common infectious diseases worldwide. Approximately one third of the world population has been exposed to the virus and an estimated 257 million people are chronically infected [1]. Regardless of the asymptomatic nature of chronic HBV infection, patients remain infectious to others and are at risk of death from cirrhosis and hepatocellular carcinoma [1]. In 2015, HBV-related complications accounted for 887,000 deaths globally [1].

The possibilities for antiviral treatment of chronic HBV infection have greatly improved over the past decades, and cost-effective drug therapies are now available [2, 3]. However, due to the asymptomatic course, most patients are unaware of their HBV infection and do not benefit from treatment. Screening for hepatitis B, aimed at early detection of chronic HBV infection with follow-up and antiviral treatment of eligible patients, is needed to reduce the economic burden of HBV-related complications and health-related suffering in Europe [4, 5]. In addition, screening could identify persons who are susceptible to infection and would benefit from vaccination [5].

In low endemic countries (< 2% hepatitis B surface antigen (HBsAg) positive), migrants born in intermediate (2–7.99% HBsAg positive) or high endemic (≥ 8% HBsAg positive) regions are an important risk group for chronic HBV infection [6]. In Belgium, the prevalence of chronic HBV infection is estimated to be 0.67% in the general population and 4.69% in first-generation migrants (FGM) born in intermediate or high endemic countries [6-8]. Migrants from intermediate or high endemic countries account for more than half of the patients with chronic HBV infection in Belgium [9]. Turkish individuals form the second largest FGM population in Europe and with a HBsAg prevalence in Turkey ranging from 2–3% in the Western part up to 7–8% in Eastern part, a substantial proportion of the Turkish migrant population may be infected with HBV [9, 10].

Most studies concerning hepatitis B testing in FGM involved southeast Asians in the USA, Canada and Australia [11]. A cross-sectional study in Turkish FGM in Germany showed a prevalence of 5% for chronic HBV infection, and this was 3% in a study conducted in the Netherlands [12, 13]. However, HBV risk factors and follow-up in Turkish FGM are mostly unclear. Furthermore, much less is known about infection prevalence, risk factors and follow-up in second-generation migrants (SGM), i.e. born in Belgium with a foreign-born parent. This is all the more important as the descendants of the FGM population grow. Regarding acute hepatitis B notification rates, a Dutch study showed a higher rate of 3.7/100,000 in SGM compared with 1.6/100,000 in native Dutch/Western persons [14].

We organized a hepatitis B testing and risk factor assessment campaign for the Turkish population in Middle Limburg, Belgium, a region with a relatively large Turkish population [15]. Here we report the prevalence of HBV infection in individuals with a Turkish background (FGM and SGM), the results of a questionnaire on risk factors, and the follow-up of patients referred to care.

Patients and methods

From 1 September 2017 until 2 May 2019, we recruited ≥ 18 year-old Turkish migrants living in the region Middle Limburg. Follow-up was concluded on 2 November 2019, 6 months after the last inclusion. The study methods have been published previously [16]. In brief, educational hepatitis B sessions with the possibility for immediate HBV screening were scheduled after the regular meetings of Turkish organizations (e.g. Islamic mosque) located in Middle Limburg. Turkish migrants could also contact the culturally targeted, multilingual (Dutch-, English- and Turkish-speaking) first author for home visits and/or for an appointment at the hepatology outpatient clinic to sign an informed consent and be screened for HBV infection. The free outreach hepatitis B testing campaign was combined with risk factor assessment by a face-to-face questionnaire. Blood samples were tested for HBsAg, antibodies against HBsAg (anti-HBs) and hepatitis B core antibodies (anti-HBc) with an electrochemiluminescence assay (Cobas 8000 e602, Roche, Germany). Both participants and their general practitioner received the test result by letter and, supplementary to this, the general practitioners were advised to contact the HBsAg positive participants by phone. All patients who tested positive for HBsAg were referred to a hepatologist for a clinical work-up and treatment program according to the European clinical practice guidelines [17]. HBsAg positive patients were divided in four phases, taking into account the presence of hepatitis B e antigen (HBeAg), serum HBV DNA levels and serum alanine aminotransferase (ALT) values [17]. Persons susceptible to HBV infection were asked to consult their general practitioner for HBV vaccination.

Questionnaire

Before hepatitis B testing, HBV risk factors were assessed through a face-to-face questionnaire (S1–S6 Figs). The questionnaire was available in the Dutch or Turkish language, and covered a total of 23 and 21 questions for males and females, respectively. The questionnaire did not cover information on intravenous drug use or sexual behaviour as these questions are sensitive and therefore socially censured; pressure to conform to societal norms could cause self-reports to be fraught with bias.

Statistical analysis

The sample size calculation was performed with the aid of Epi Info® (version 7.2). Since data on country of birth in Middle Limburg are unavailable and data on nationality do not represent country of birth, the number of study participants per age group was calculated so that the results of the study group agree with that of the Turkish population living in Middle Limburg with a significance level of 5%. This is important for the extrapolation of the study results to the general Turkish population (Table 1).

Table 1

Composition of the study group compared with the composition of the Turkish population living in Middle Limburg regarding age and gender.

Age (years)	Total	18–39	40–59	≥ 60	Male	Female
Study group (N)	1,081	433	511	137	468	613
Study group (%)	100	40.1	47.3	12.6	43.3	56.7
Turkish Middle Limburg population (%)	100	53.9	35.4	10.7	50.5	49.5

To assess the impact of universal HBV vaccination in Belgium among Turkish SGM, we stratified HBsAg, anti-HBc and/or anti-HBs prevalence into two birth cohorts (1930–1986 and 1987–2001). This cutoff was chosen as the free-of-charge HBV vaccination program in infants since September 1999 with catch-up vaccination for 10–13 year-olds covered children born after 1987 in Belgium [18].

Since participants could be part of the same household, resulting in violation of the assumption of independent observations for classical tests such as logistic regression, univariate generalized estimating equations (GEE) were used to investigate the influence of the different variables on the presence of past or current HBV infection (anti-HBc positive), chronic HBV infection (HBsAg positive) and vaccination status (solely anti-HBs positive). The correlation structure in these GEE is assumed to be of the ‘compound symmetry’ type, specifying that all observations within the same cluster are equally correlated. Although this might not be the correct assumption, GEE has been shown to be robust to misspecification of the working correlation structure [19].

Variables showing significant association (p < .20) in the univariate analyses were subsequently included in a multiple GEE model. As origin and educational level of mother and father were highly correlated, only maternal factors were included in the models. Backward selection was used to obtain a final model. In order to correct for differences between the sample and the Middle-Limburg population, weights were included in all GEE models. Weighting was done based on the combination of age and gender.

Ethical approval

The study was undertaken in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the medical ethics committees of Hasselt University and Hospital East-Limburg (17-039U). All participants gave their informed consent in writing prior to inclusion.

Results

In total 1,081 Turkish migrants were tested for HBV infection; 1,047 of the 1,079 (97.0%) persons present at the educational meetings in a Turkish organization and all 34 (100.0%) participants present at home visits did go for testing. Less than half of the study participants were male (43.3%), and the mean age was 44 ± 13.7 years. The majority of the participants were born in Turkey (58.1%), 41.9% were born in Belgium.

Blood samples were insufficient for anti-HBs testing in four participants. In 21.5% (232/1,081) there was evidence of a past or recent HBV infection (anti-HBc positive), 2.4% (26/1,081) had a chronic HBV infection (HBsAg positive), 22.9% (247/1,077) of the samples were solely anti-HBs positive (‘vaccinated’ serostatus) and 55.5% (598/1,077) appeared to be susceptible for HBV infection (negative HBV markers).

Past or recent HBV infection

Past or recent HBV infection in FGM was apparent in 206/628 (32.8%) with differences between males and females, i.e. 40.4% (110/272) vs 27.0% (96/356), respectively, p = .001. Among FGM, anti-HBc prevalence in 18–39 year-olds, 40–59 year-olds and >60 year-olds was 13.2% (14/106), 31.9% (123/385) and 50.4% (69/137), respectively, p < .001.

Gender difference regarding anti-HBc prevalence was not seen in Turkish SGM, i.e. 5.6% (11/196) in males vs 5.8% (15/257) in females, p = 1.000. Anti-HBc prevalence in Turkish SGM born after 1987 was 1.1% (2/190), and was higher for those SGM born before 1987, i.e. 9.1% (24/263), p < .001. Older age was associated with past or recent HBV infection in SGM, i.e. 4.0% (13/327) in 18–39 year-olds vs 10.3% (13/126) in 40–59 year-olds, p = .018. There were no SGM 60 years or older.

Factors associated with past or recent HBV infection in the weighted univariate GEE are shown in Table 2. From the weighted multiple GEE analyses as shown in Table 3, it can be seen that male gender (p = .021), older age (p < .001), FGM (p < .001), lower (i.e. none or primary) educational level of the mother (p = .003), HBV infected mother (p = .008), HBV infected siblings (p = .002), HBV infected other family member (p = .004), gynaecological examination in Turkey or unsafe male circumcision (p = .032), dental treatment in Turkey (p = .049), and treatment with needles in Turkey (p = .012) significantly increased the odds of anti-HBc positivity.

Table 2

Prevalence of past or recent hepatitis B virus infection by different risk factors among the total study population (n = 1,081) (weighted univariate GEE).

	n	N	Prevalence (%)	P value	Crude OR (95% CI)
Overall	232	1,081	21.5%	-	-
Gender				.038
Male	121	468	25.9%		1.38 (1.02–1.86)
Female	111	613	18.1%		(ref)
Age group				< .001
18–39 years	27	433	6.2%		(ref)
40–59 years	136	511	26.6%		5.73 (3.67–8.92)
≥ 60 years	69	137	50.4%		16.26 (9.55–27.67)
Ethnicity				< .001
FGM	206	628	32.8%		8.84 (5.59–13.97)
SGM	26	453	5.7%		(ref)
Year of immigration (if FGM)				< .001
Before 1987	144	363	39.7%		2.33 (1.58–3.42)
Year 1987 or later	61	264	23.1%		(ref)
Southeastern Anatolian origin of mother				.470
Yes	15	59	25.4%		1.28 (0.68–2.42)
No	216	971	22.2%		(ref)
Mother’s educational level				< .001
None	167	570	29.3%		7.65 (0.96–60.73)
Primary school	61	380	16.5%		3.57 (0.45–28.64)
Secondary school	3	123	2.4%		0.37 (0.03–4.15)
High school/University	1	13	7.7%		(ref)
HBV infected partner				.698
Yes	7	25	28.0%		1.23 (0.43–3.50)
No/Unknown	225	1,056	21.3%		(ref)
HBV infected mother				.005
Yes	17	37	45.9%		4.21 (1.98–8.99)
No/Unknown	215	1,044	20.6%		(ref)
HBV infected father				.016
Yes	2	24	8.3%		0.24 (0.05–1.17)
No/Unknown	230	1,057	21.8%		(ref)
HBV infected siblings				.003
Yes	21	45	46.7%		3.77 (1.81–7.87)
No/Unknown	211	1,036	20.4%		(ref)
HBV infected other family member				.008
Yes	26	70	37.1%		2.65 (1.47–4.80)
No/Unknown	206	1,011	20.4%		(ref)
Sharing toothbrushes regularly				< .001
Yes	62	188	33.0%		2.35 (1.59–3.47)
No	170	892	19.1%		(ref)
Sharing nail clippers				.296
Yes	208	991	21.0%		0.74 (0.43–1.25)
No	24	89	27.0%		(ref)
Sharing razors				.609
Yes	36	170	21.2%		1.13 (0.73–1.75)
No	196	910	21.5%		(ref)
Sharing used towels				.164
Yes	206	945	21.8%		1.38 (0.85–2.24)
No	26	135	19.3%		(ref)
Eating from the same plate				.423
Yes	201	927	21.7%		1.19 (0.77–1.84)
No	31	153	20.3%		(ref)
Gynaecological examination in Turkey (if female)				.003
Yes	30	99	30.3%		2.73 (1.60–4.67)
No	81	514	15.8%		(ref)
Circumcision (if male)				.004
Collective	44	118	37.3%		2.18 (1.34–3.56)
Alone	66	305	21.6%		(ref)
Circumcision not carried out by medical doctor (if male)				< .001
Yes	84	228	36.8%		5.24 (2.76–9.94)
No	14	153	9.2%		(ref)
Gynaecological examination in Turkey or unsafe male circumcision				< .001
Yes	115	330	34.9%		2.92 (2.12–4.02)
No	117	751	15.6%		(ref)
Blood transfusion				.062
Yes	44	167	26.3%		1.52 (1.01–2.27)
No	188	914	20.6%		(ref)
Dental treatment in Turkey				< .001
Yes	147	430	34.2%		4.36 (3.17–5.98)
No	85	651	13.1%		(ref)
Surgery in Turkey				< .001
Yes	50	133	37.6%		3.12 (2.05–4.76)
No	182	948	19.2%		(ref)
Treatment with needles in Turkey				< .001
Yes	107	322	33.2%		2.82 (2.04–3.91)
No	125	759	16.5%		(ref)
Body piercing/tattooing/earlobe perforation in Turkey				.009
Yes	84	327	25.7%		1.58 (1.14–2.20)
No	148	754	19.6%		(ref)
Fish spa treatment				.058
Yes in Turkey	9	64	14.1%		0.54 (0.25–1.14)
No/Other	223	1,017	21.9%		(ref)

Abbreviation: GEE: generalized estimating equations; OR: odds ratio; CI: confidence interval; HBV: hepatitis B virus; FGM: first-generation migrants; SGM: second-generation migrants.

First-generation migrants: foreign-born individuals; second-generation migrants: individuals born in Belgium with foreign-born parents; unsafe male circumcision: collective circumcision and/or circumcision not carried out by medical doctor.

Table 3

Association of past or recent hepatitis B virus infection to different risk factors among the total study population (n = 1,081) (weighted multiple GEE model).

Parameter		Estimate (SE)	p-value	aOR (95% CI)
(intercept)		-4.39 (0.79)
Gender			.021
	Male (vs Female)	0.46 (0.19)		1.58 (1.08–2.31)
Age group			< .001
	40–59 years (vs 18–39 years)	0.80 (0.25)		2.21 (1.36–3.62)
	≥ 60 years (vs 18–39 years)	1.50 (0.32)		4.50 (2.39–8.47)
Ethnicity			< .001
	FGM (vs SGM)	1.22 (0.26)		3.40 (2.03–5.69)
Mother’s educational level			.003
	None (vs High school/University)	0.61 (0.80)		1.84 (0.38–8.88)
	Primary (vs High school/University)	0.53 (0.80)		1.70 (0.35–8.20)
	Secondary (vs High school/University)	-1.18 (1.05)		0.31 (0.04–2.41)
HBV infected mother			.008
	Yes (vs No/Unknown)	1.51 (0.45)		4.52 (1.89–10.84)
HBV infected siblings			.002
	Yes (vs No/Unknown)	1.53 (0.40)		4.61 (2.13–10.01)
HBV infected other family member			.004
	Yes (vs No/Unknown)	1.35 (0.39)		3.86 (1.80–8.30)
Gynaecological examination in Turkey or unsafe male circumcision			.032
	Yes (vs No)	0.41 (0.19)		1.51 (1.04–2.21)
Dental treatment in Turkey			.049
	Yes (vs No)	0.40 (0.20)		1.50 (1.01–2.21)
Treatment with needles in Turkey			.012
	Yes (vs No)	0.49 (0.19)		1.63 (1.13–2.36)

Abbreviations: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: confidence interval; HBV: hepatitis B virus; FGM: first-generation migrants; SGM: second-generation migrants.

First-generation migrants: foreign-born individuals; second-generation migrants: individuals born in Belgium with foreign-born parents; unsafe male circumcision: collective circumcision and/or circumcision not carried out by medical doctor.

Multiple GEE analyses were also conducted for males and females separately as well as for FGM and SGM (S1–S4 Tables). The final model for males and females included age (p = .006 and p < .001), FGM (p < .001 and p < .001) and treatment with needles in Turkey (p = .030 and p = .003). In males, HBV infected siblings (p = .022) and circumcision not conducted by a medical doctor were additional independent risk factors.

Independent risk factors for recent or past HBV infection among FGM included age (p < .001), HBV infected mother (p = .042), HBV infected siblings (p = .024), gynaecological examination in Turkey or unsafe male circumcision (p < .001), and treatment with needles in Turkey (p = .003). Among SGM, risk factors included HBV infected other family member (p = .010) and treatment with needles in Turkey (p = .030).

Sixty-five patients with past or recent HBV infection had a family member with HBV infection: among seven (10.8%) patients only the partner was infected, 14 (21.5%) with HBV infected mother only, one (1.5%) with HBV infected father only, 16 (24.6%) with HBV infected siblings only, 19 (29.2%) had another family member with HBV infection, three (4.6%) with HBV infection among mother and siblings, one (1.5%) with HBV infected father and siblings, and four (6.2%) with HBV infected siblings and other family member. Therefore HBV infected mother could potentially explain 17/65 (26.2%) anti-HBc positive cases with a positive family history of HBV infection.

Chronic HBV infection

Of the 26 HBsAg positive individuals, 19 were FGM, leading to a HBsAg prevalence of 3.0% (19/628) in FGM. Compared to females, male FGM had a higher prevalence of chronic HBV infection (5.5% (15/272) in males vs 1.1% (4/356) in females, p = .002).

Gender difference regarding chronic HBV infection was not seen in Turkish SGM, i.e. 1.5% (3/196) in males vs 1.6% (4/257) in females, p = 1.000. Overall, 1.5% (7/453) SGM were HBsAg positive; only one out of seven HBsAg positive SGM was born after 1987. This corresponds to a HBsAg positivity of 0.5% (1/190) and 2.3% (6/263) in those born after and before 1987, respectively, p = .135. All but one had HBV infection in the family: one with HBV infection in mother only, two with HBV infection in siblings only, one with HBV infection in another family member only and two with HBV infection in siblings and another family member.

S5 Table shows factors associated with chronic HBV infection in the weighted univariate GEE. From the weighted multiple GEE analyses as shown in Table 4, it can be seen that older age (p = .022) and gynaecological examination in Turkey or unsafe male circumcision (p = .004) significantly increased the odds, while body piercing/tattooing/earlobe perforation in Turkey resulted in a lower odds of chronic HBV infection (p = .009).

Table 4

Association of chronic HBV infection to different risk factors among the total study population (n = 1,081) (weighted multiple GEE).

Parameter		Estimate (SE)	p-value	aOR (95% CI)
(intercept)		-5.28 (0.65)
Age group			.022
	40–59 years (vs 18–39 years)	1.28 (0.64)		3.59 (1.03–12.48)
	≥ 60 years (vs 18–39 years)	1.49 (0.81)		4.45 (0.90–21.92)
Gynaecological examination in Turkey or unsafe male circumcision			.004
	Yes (vs No)	1.48 (0.46)		4.37 (1.78–10.71)
Body piercing/tattooing/earlobe perforation in Turkey			.009
	Yes (vs No)	-1.13 (0.57)		0.32 (0.11–0.99)

Abbreviations: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: confidence interval.

Unsafe male circumcision: collective circumcision and/or circumcision not carried out by medical doctor.

Follow-up in patients with chronic HBV infection

Eleven of 26 chronically infected patients were unaware of their HBV status and the other 15 were already linked to care (Fig 1). Thus, the percentage of newly diagnosed HBsAg positive patients was 1.02% (11/1,081). Two patients were referred to another hospital, one could not be linked to care due to incorrect contact details and the remaining eight patients were seen at the Department of Gastroenterology and Hepatology of Hospital East-Limburg.

Fig 1

Follow-up results in patients with chronic HBV infection.

Abbreviations: HBV: hepatitis B virus; ALT: alanine aminotransferase.

Out of the 15 patients that were already linked to care, 11 were classified as HBeAg-negative chronic infection, three as HBeAg-negative chronic hepatitis and one with HBeAg-positive chronic hepatitis. Both patients referred to another hospital and the eight patients evaluated in our hospital were categorized into two groups according to the HBV DNA (≥ 2,000 IU/mL vs < 2,000 IU/mL) and ALT level (> 40 IU/L vs ≤ 40 IU/L) at the first visit (Fig 1). There was no evidence of cirrhosis or HCC on abdominal ultrasound. Advanced liver disease was suspected in one patient based on transient elastography value ≥ 10 kPa. However, liver biopsy revealed F1 (portal fibrosis without septa) and the presence of nonalcoholic steatohepatitis (NASH). Within one year follow-up, none of the ten newly HBsAg positive patients had an indication for antiviral treatment. Two patients were lost to follow-up after the first visit for reasons unknown.

Solely anti-HBs positive

Regarding our question on HBV vaccination, a total of 22.2% (239/1,076) indicated to be vaccinated, 26.9% (289/1,076) were not vaccinated and history of HBV vaccination was unknown in the remaining 50.9% (548/1,076) participants. Among those with a history of vaccination (n = 239), 29 (12.1%) and 1 (0.4%) were anti-HBc positive and HBsAg positive, respectively.

Solely anti-HBs positivity in Turkish SGM born after 1987 was 72.1% (137/190), and was lower for those SGM born before 1987 (21.5%, 56/261), p < .001. S6 Table shows factors associated with vaccination status in the weighted univariate GEE. For solely anti-HBs positivity (i.e. vaccination status), the final model included gender (p = .008), age group (p < .001), ethnicity (p < .001), mother’s educational level (p = .007) and vaccination history (p < .001) (Table 5).

Table 5

Association of vaccination status (solely anti-HBs positive) to different risk factors among the total study population with information on anti-HBs (n = 1,077) (weighted multiple GEE).

Parameter		Estimate (SE)	p-value	aOR (95% CI)
(intercept)		1.50 (0.69)
Gender			.008
	Male (vs Female)	-0.54 (0.20)		0.58 (0.39–0.86)
Age group			< .001
	40–59 years (vs 18–39 years)	-1.30 (0.23)		0.27 (0.18–0.43)
	≥ 60 years (vs 18–39 years)	-1.74 (0.54)		0.18 (0.06–0.51)
Ethnicity			< .001
	FGM (vs SGM)	-1.18 (0.22)		0.31 (0.20–0.47)
Mother’s educational level			.007
	None (vs High school/University)	-1.51 (0.68)		0.22 (0.06–0.83)
	Primary (vs High school/University)	-1.23 (0.68)		0.29 (0.08–1.11)
	Secondary (vs High school/University)	-0.61 (0.69)		0.54 (0.14–2.11)
Vaccination history			< .001
	Not vaccinated/Unknown (vs Vaccinated)	-1.90 (0.21)		0.15 (0.10–0.22)

Abbreviations: GEE: generalized estimating equations; SE: standard error; aOR: adjusted odds ratio; CI: confidence interval; FGM: first-generation migrants; SGM: second-generation migrants.

First-generation migrants: foreign-born individuals; second-generation migrants: individuals born in Belgium with foreign-born parents; unsafe male circumcision: collective circumcision and/or circumcision not carried out by medical doctor.

Susceptible for HBV infection

Six months after the last inclusion, 19.1% (44/230 susceptible individuals with follow-up information on vaccination) of the participants susceptible for HBV infection initiated vaccination.

Discussion

In addition to the screening of FGM, i.e. those born in Turkey, our study is one of the first hepatitis B screening projects in Europe targeting a substantial proportion of SGM, i.e. those born in Belgium with a foreign-born parent. First, we show that outreach testing was well-accepted in Turkish migrants. Although Turkish migrants could opt for screening during home visits or at the hepatology outpatient clinic, the majority (97%) were tested immediately after educational sessions in Islamic mosques and Turkish organizations.

Our finding of 3% HBsAg positivity in Turkish FGM is in line with previous findings reported in the Netherlands and Germany (HBsAg prevalence varying from 3–5%), and reflects the high prevalence in the country of origin [10, 12, 13, 20]. However, the 1.5% prevalence of chronic HBV infection in Turkish SGM is higher than the reported 0.7% HBsAg prevalence in native Belgians [6-8]. This finding is novel and might in part be explained by the interaction of high prevalence in the country of origin and suboptimal coverage by primary prevention strategies in the country of birth. None of the seven cases of SGM with chronic HBV infection in our study were born after 1999, which is the year universal HBV vaccination in infants was implemented in Belgium. However, although six HBsAg positive SGM were born before 1987, one was born between 1987 and 1999, a birth cohort that should have been covered by the catch-up vaccination in 10–13 year-olds since 1999. In this matter, lowest immunization coverage rates in Belgium were found in those born between 1990 and 1998 [21]. Moreover, prior studies indicated that non-European origin and low educational level of the mother were associated with a decreased odds of vaccination coverage in children [22, 23]. In our study, mother’s educational level was associated with vaccination coverage.

In our Turkish migrant study population, HBV infection in the mother could potentially explain less than one third of the patients with past or recent HBV infection. HBV infection in siblings possibly accounted for another major part of past or recent HBV infection in our study. In Turkey, perinatal transmission of HBV infection is uncommon as HBeAg positivity in pregnant chronic HBV patients is very low [24]. The infection is mostly acquired in childhood through horizontal transmission, i.e. that occurring through non-sexual and non-parenteral contact beyond six months of age, in childhood and pre-adolescent period [15, 24]. In the Turkish families, most of the mothers are housewives and mostly stay at home as caretakers for the children. Although the mother is important for horizontal HBV transmission through non-sexual close contact, sibling-to-sibling horizontal transmission might also be an important route of HBV infection [25-27]. Siblings share the same environment, experience the same cultural and family traditions, which may be associated with increased risks of transmission.

Physicians from countries with a selective vaccination program targeting groups at risk of HBV infection only, instead of adding a universal vaccination program, should be aware of horizontal transmission through non-sexual close contact [28]. Children are more likely to have contact with each other’s body fluid and are therefore at risk of horizontal transmission through non-sexual close contact. Skin lesions or sharing contaminated material such as towels, toothbrushes or razor blades has been shown to play a role in horizontal transmission through non-sexual close contact [24]. In this matter, sharing toothbrushes regularly was univariately associated with past or recent HBV infection in our study population. However, this association diminished when accounting for other risk factors. The most important independent risk factors for past or recent HBV infection found in our study were male gender, older age, being a FGM, low educational level of the mother, a family history of HBV infection, gynaecological examination in Turkey or unsafe male circumcision, dental treatment in Turkey and treatment with needles in Turkey. These findings are in line with previous studies conducted in Turkish migrants living in Europe and studies conducted in Turkey [12, 13, 20, 24, 25].

For a screening program aimed at secondary prevention of HBV infection, access to care is inevitable to reduce the economic burden of HBV-related complications. In Greece, it is estimated that less than half of the patients diagnosed with HBV were referred and received the appropriate care [29]. This number was between 40% and 66% in the USA [30]. Most screening projects provide data on the HBsAg prevalence but do not assess referral, disease stage and initiation of antiviral therapy. We showed a successful referral of more than 90% newly diagnosed patients with chronic HBV infection. The implementation of a pre-screening phase with awareness activities among general practitioners and delegates of Turkish organizations as well as the impact of educational meetings on the Turkish migrant population to make an informed decision to participate in screening, might explain the good compliance to referral [11]. Within one year of follow-up, all newly diagnosed patients had HBeAg-negative chronic infection based on normal ALT levels, low HBV DNA levels, HBeAg negative status and no significant fibrosis [31]. During follow-up, none had an indication for antiviral therapy, but continued monitoring was still recommended for risk of HBV reactivation, advanced liver disease and HCC, especially those with HBV DNA levels > 2,000 IU/mL [31-33].

Less than one in five susceptible individuals initiated hepatitis B vaccination. This is lower than the reported 52–89% among migrant populations in the USA and might be explained by 1) dissimilar populations, 2) free of charge vaccination or vaccination at a reduced price and 3) the use of a combination of letters, phone calls, e-mail and in-person appointments to contact susceptible individuals for vaccination in these studies [11, 34–38]. This is in contrast to our study, in which susceptible individuals were invited by a letter to consult their general practitioner for hepatitis B vaccination in accordance with standard practices in Belgium. The uptake of vaccination was also low (22%) in an outreach screening project among Chinese migrants in the Netherlands [39].

This study had a few limitations. First, this study could be underpowered to find significant associations between certain risk factors and hepatitis B viral markers, as sample size calculation was performed in such a way that the distribution per age group was similar to that of the Turkish population in Middle Limburg. Second, although a face-to-face questionnaire could limit the risk of misinterpretation and incomplete entries, certain socially undesirable behaviours could have been underreported. In this matter, the questionnaire did not cover questions regarding intravenous drug use, men who have sex with men and multiple unsafe heterosexual contacts since the answers to these questions are ought to be unreliable in this Turkish population in which the majority of people identify with Islam. Third, this study describes the results of hepatitis B screening and risk factor assessment in the Turkish population in Middle Limburg, Belgium. It is unknown whether observations from our study could be extrapolated for the European region. However, the collection of several sociodemographic factors and HBV risk factors in the current study allow a detailed characterization of the study population and consequently in-depth comparisons with other studies could be established.

In conclusion, we found that outreach testing and referral to specialist care was clinically effective in the Turkish migrant population. We confirmed that HBV prevalence among Turkish FGM reflects the high prevalence in the country of origin. An important finding was the relatively high infection prevalence in Turkish SGM compared with prevalence estimates for the general population in Belgium and other European countries. Given WHO’s ambitious goal to eliminate viral hepatitis by 2030, national HBV screening for Turkish FGM should be implemented and might be considered in SGM not covered by primary prevention strategies, taking into account the asymptomatic nature of disease and misleading normal levels of ALT. Screening projects aimed at SGM are needed to further inform future screening policies for this population.

Questionnaire for males (Dutch version).

(PDF)

Click here for additional data file.

Questionnaire for males (Turkish version).

(PDF)

Click here for additional data file.

Questionnaire for males (English version).

(PDF)

Click here for additional data file.

Questionnaire for females (Dutch version).

(PDF)

Click here for additional data file.

Questionnaire for females (Turkish version).

(PDF)

Click here for additional data file.

Questionnaire for females (English version).

(PDF)

Click here for additional data file.

Association of past or recent hepatitis B virus infection to different risk factors among the male study population (n = 468) (weighted GEE model).

(PDF)

Click here for additional data file.

Association of past or recent hepatitis B virus infection to different risk factors among the female study population (n = 623) (weighted GEE model).

(PDF)

Click here for additional data file.

Association of past or recent hepatitis B virus infection to different risk factors among first-generation migrants (n = 628) (weighted GEE model).

(PDF)

Click here for additional data file.

Association of past or recent hepatitis B virus infection to different risk factors among second-generation migrants (n = 453) (weighted GEE model).

(PDF)

Click here for additional data file.

Prevalence of chronic hepatitis B virus infection by different risk factors among the total population (n = 1,081) (weighted univariate GEE).

(PDF)

Click here for additional data file.

Vaccination status (solely anti-HBs positive) by different risk factors among the total population with information on anti-HBs (n = 1,077) (weighted univariate GEE).

(PDF)

Click here for additional data file.

17 Mar 2020

PONE-D-20-00619

Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium.

PLOS ONE

Dear Dr. Koc,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

The data is well presented and technically sounds. Both reviewers made good comments about the paper. Please read carefully the recommendation of reviewers and editor that is presented below.

==============================

We would appreciate receiving your revised manuscript by May 01 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Livia Melo Villar

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (a) whether consent was informed and (b) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

3. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

4. Please ensure you have thoroughly discussed any potential limitations of this study within the Discussion section.

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. Thank you for stating the following financial disclosure:

"This work was supported by Gilead Sciences by an unrestricted grant registered as V 2331 at Hasselt University."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please respond by return e-mail so that we can amend your financial disclosure and competing interests on your behalf.

7. Thank you for stating the following in the Competing Interests section:

"None"

We note that you received funding from a commercial source: "Gilead Sciences"

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Additional Editor Comments (if provided):

Dear Author,

Thanks for sending the paper intitled: "Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium". This paper reports the prevalence of HBV infection in individuals with a Turkish background (FGM and SGM), the results of a questionnaire on risk factors, and the follow-up of patients referred to care. The data is well presented and technically sounds.

Each reviewer made comments to this revision that should be answered.

Specific Comments of Editor:

I also recommend to include more information regarding population recruitment in methods section.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The study is extremely relevant. Since immigrants are key populations in the elimination of HBV. These populations are often neglected and access to information and effective prevention and treatment is not provided to them. It is important to highlight the inclusion of those born in Belgium to immigrant parents. For, the customs, culture and prejudice against this population continue in this generation, which may favor a transmission network that needs to be interrupted in terms of global public health.

Study considerations:

I did not find the part of the title "Early detection of chronic hepatitis B" interesting.

Why do you think it was early detection? It would only be more correct, detection of chronic hepatitis B.

The summary does not speak of the most important risk factors found in the study.

In the introduction: line 92-94. Paragraph 3 is confused. Are you talking about all countries in general, or where did the study take place?

The questions reported in lines 137-139 are very important for the analysis of HBV risk factors, due to sexual and parenteral transmission. Despite being very particular factors, they need to be taken into account. They should be highlighted as limitations of the study and in an upcoming study to be evaluated.

This should be noted, that these factors were not considered to be risky, as the necessary information was not obtained.

Was the chronic infection reported on line 190 (HbsAg + and anti-HBc +)?

Reviewer #2: Dr Koc et al. examined the prevalence of HBV in Turkish migrants in Belgium and determined the risk factors.

The finding that the horizontal transmission seems an important route for the infection is intriguing.

The necessity for screening projects aimed at second-generation migrates is an important message.

The research is technically sound and the data are probably precious in this field.

I do not have any special comments on this study.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

21 Apr 2020

Journal requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Answer: We changed accordingly.

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (a) whether consent was informed and (b) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

Answer: Minors were not included in the current study as stated under Patients and methods. In the methods section we included the following sentence: All participants gave their informed consent in writing prior to inclusion. (see lines 210-211)

3. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

Answer: We used separate questionnaires for men and women, available in Dutch and Turkish language as previously stated in the manuscript. In addition to the original questionnaires we now provide the English version as supporting information (see S1 – S6 Figs).

4. Please ensure you have thoroughly discussed any potential limitations of this study within the Discussion section.

Answer: Study limitations are now depicted within the discussion section as follows: This study had a few limitations. First, this study could be underpowered to find significant associations between certain risk factors and hepatitis B viral markers, as sample size calculation was performed in such a way that the distribution per age group was similar to that of the Turkish population in Middle Limburg. Second, although a face-to-face questionnaire could limit the risk of misinterpretation and incomplete entries, certain socially undesirable behaviours could have been underreported. In this matter, the questionnaire did not cover questions regarding intravenous drug use, men who have sex with men and multiple unsafe heterosexual contacts since the answers to these questions are ought to be unreliable in this Turkish population in which the majority of people identify with Islam. Third, this study describes the results of hepatitis B screening and risk factor assessment in the Turkish population in Middle Limburg, Belgium. It is unknown whether observations from our study could be extrapolated for the European region. However, the collection of several sociodemographic factors and HBV risk factors in the current study allow a detailed characterization of the study population and consequently in-depth comparisons with other studies could be established. (see lines 425-439)

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Answer: Data will be made available in the following repository: Koc, ÖM et al. (2020), Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium., Dryad, Dataset, https://doi.org/10.5061/dryad.4f4qrfj87

6. Thank you for stating the following financial disclosure: "This work was supported by Gilead Sciences by an unrestricted grant registered as V 2331 at Hasselt University."

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." Please respond by return e-mail so that we can amend your financial disclosure and competing interests on your behalf.

Answer: the funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

7. Thank you for stating the following in the Competing Interests section:

"None"

We note that you received funding from a commercial source: "Gilead Sciences"

Answer: We apologize for the incomplete conflicts of interest statement. Hereby we provide a complete list of competing interests:

ÖK received travel grants from Gilead Sciences and his institution received grants from Gilead Sciences, AbbVie, MSD and CyTuVax B.V. NH is holder of the chair in evidence-based vaccinology supported though a gift by Pfizer. All outside the submitted work. RB has received travel grants from AbbVie, Gilead Sciences and MSD to attend scientific congresses and research grants from Gilead and MSD. DB has received travel grants from AbbVie and a research grant from Gilead. PVD acts as chief and principal investigator for vaccine trials conducted on behalf of the University of Antwerp, for which the University obtains research grants from vaccine manufacturers; speakers fees for presentations on vaccines are paid directly to an educational fund held by the University of Antwerp. PVD receives no personal remuneration for this work. GR has received research grants from AbbVie, MSD, Janssen Pharmaceuticals, and has acted as a consultant/advisor for AbbVie, MSD, Gilead Sciences and Bristol-Myers Squibb.

This does not alter our adherence to PLOS ONE policies on sharing data and materials.

8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Answer: We have included captions for our 11 supporting files at the end of our manuscript. The citations were changed in line with the PLOS ONE requirements.

Editor Comments:

Thanks for sending the paper intitled: "Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium". This paper reports the prevalence of HBV infection in individuals with a Turkish background (FGM and SGM), the results of a questionnaire on risk factors, and the follow-up of patients referred to care. The data is well presented and technically sounds.

Each reviewer made comments to this revision that should be answered.

1. I also recommend to include more information regarding population recruitment in methods section.

Answer: For the interpretation of the study, we included the following sentence: In brief, educational hepatitis B sessions with the possibility for immediate HBV screening were scheduled after the regular meetings of Turkish organizations (e.g. Islamic mosque) located in Middle Limburg. Turkish migrants could also contact the culturally targeted, multilingual (Dutch‐, English‐ and Turkish‐speaking) first author for home visits and/or for an appointment at the hepatology outpatient clinic to sign an informed consent and be screened for HBV infection. (see lines 146-151)

Reviewer#1:

The study is extremely relevant. Since immigrants are key populations in the elimination of HBV. These populations are often neglected and access to information and effective prevention and treatment is not provided to them. It is important to highlight the inclusion of those born in Belgium to immigrant parents. For, the customs, culture and prejudice against this population continue in this generation, which may favor a transmission network that needs to be interrupted in terms of global public health.

1. I did not find the part of the title "Early detection of chronic hepatitis B" interesting.

Why do you think it was early detection? It would only be more correct, detection of chronic hepatitis B.

Answer: Our hepatitis B screening targeted at the Turkish migrant population is a form of secondary prevention aimed to reduce the impact of HBV infection. This is done by detecting HBV infection as soon as possible to prevent disease progression. It is well known that a chronically infected hepatitis B patient has no or minimal symptoms until the development of serious late complications such as cirrhosis, decompensated cirrhosis and hepatocellular carcinoma. Since none of the newly diagnosed hepatitis B patients in the current study had cirrhosis at presentation, we would like to underline the importance of early detection.

2. The summary does not speak of the most important risk factors found in the study.

Answer: You are correct. We included the most important risk factors in the summary. (see lines 65-69)

3. In the introduction: line 92-94. Paragraph 3 is confused. Are you talking about all countries in general, or where did the study take place?

Answer: This is a general statement indicating that migrants from endemic regions (HBsAg positivity 2-7.99% for intermediate endemic regions and >8% for high endemicity) are an important risk group in regions with low endemicity for hepatitis B (HBsAg positivity <2%), such as Western Europe.

4. The questions reported in lines 137-139 are very important for the analysis of HBV risk factors, due to sexual and parenteral transmission. Despite being very particular factors, they need to be taken into account. They should be highlighted as limitations of the study and in an upcoming study to be evaluated.

This should be noted, that these factors were not considered to be risky, as the necessary information was not obtained.

Answer: We agree with the reviewer that information regarding intravenous drug use and high-risk sexual behavior is very important for the analysis of HBV risk factors. However, this information was not collected since the answers to these sensitive questions are probably unreliable in the Turkish migrant population in which the majority are Muslims.

In accordance with the journal requirements we included this as a limitation within the discussion. Study limitations are now depicted within the discussion section as follows: Second, although a face-to-face questionnaire could limit the risk of misinterpretation and incomplete entries, certain socially undesirable behaviours could have been underreported. In this matter, the questionnaire did not cover questions regarding intravenous drug use, men who have sex with men and multiple unsafe heterosexual contacts since the answers to these questions are ought to be unreliable in this Turkish population in which the majority of people identify with Islam. (see lines 428-432)

5. Was the chronic infection reported on line 190 (HbsAg + and anti-HBc +)?

Answer: HBsAg positivity was considered as chronic HBV infection in the current study. All HBsAg patients were also anti-HBc positive. Considering the prospective follow-up of HBsAg positive individuals, we indeed confirmed that they were chronically infected with HBV infection.

Reviewer #2:

Dr Koc et al. examined the prevalence of HBV in Turkish migrants in Belgium and determined the risk factors.

The finding that the horizontal transmission seems an important route for the infection is intriguing.

The necessity for screening projects aimed at second-generation migrates is an important message.

The research is technically sound and the data are probably precious in this field.

I do not have any special comments on this study.

Answer: we would like to thank the reviewer for her/his kind remarks.

Submitted filename: Response to reviewers.docx

Click here for additional data file.

2 Jun 2020

Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium.

PONE-D-20-00619R1

Dear Dr. Koc,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Livia Melo Villar

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Dear Author,

The suggestions and corrections were made as requested.

Best regards

Livia Villar

Reviewers' comments:

16 Jul 2020

PONE-D-20-00619R1

Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium.

Dear Dr. Koc:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Livia Melo Villar

Academic Editor

PLOS ONE